Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)
- Sponsor
- Region Örebro County
- Study ID
- NCT03983031
- Phase
- PHASE1
- Status
- Completed
Conditions
- Obsessive-Compulsive Disorder
- Treatment Resistant Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUGInfusion
Study Details
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.
Key Dates
- Start date
- Aug 8, 2019
- Status verified
- May 2022
- Primary completion
- Mar 31, 2022
- Completion
- Mar 31, 2022
Study Design
- Enrollment
- 11 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Yale-Brown obsessive- compulsive scale (Y-BOCS) [ Time Frame: week 20 ]
Related Studies
- Locating Biomarkers in OCD Through Behavioral TasksNot Yet Recruiting · Baylor College of Medicine · Pittsburgh, Pennsylvania
- Efficacy of Nitrous Oxide in OCD: Pilot StudyPHASE2 · Recruiting · Stanford University · Stanford, California
- Caloric Vestibular Stimulation for Modulation of Insight in Obsessive-Compulsive Spectrum DisordersRecruiting · Stanford University · Stanford, California
- Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCDPHASE1/PHASE2 · Recruiting · Yale University · New Haven, Connecticut